1st Quarter Review Ending Mar 31, 2015
Jan 9 - InVivo announces the reopening of subject enrollment for the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. To date, there have been no reported serious safety events with the study’s first subject.
Jan 12 - Investor Presentation updated
Jan 15 - SC 13D/A- Amendment #5 – Former CEO Frank Reynolds now owns 5,013,260 (5.3% )
Jan 21 - InVivo reports three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold - Motor, Sensory, Bowel, and Bladder Function Improvement with No Reported Serious Adverse Events. Dr. Theodore said, “I am very pleased with the first subject’s progress since the scaffold was implanted. In my experience, this degree of sensory and motor improvement is unexpected.” FactMan: it doesn’t get much better than this!!!
Jan 22 - InVivo announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial. FactMan: very significant since this took only 13 days since enrollment was reopened and it is now very likely ongoing pilot study will be completed in 2015.
Jan 26 – Investor Presentation updated.
Jan 29 - InVivo announces $12 Million Registered Direct Offering. FactMan: With the $1.4375 warrant exercise that will raise an additional $10 million they should be funded for all of 2015, 2016 and 2017.
Feb 2 - SC 13G - Sabby Management, LLC acquires 7,750,000 shares (as part of Jan 29. 2015 secondary offering)
Feb 3 - SC 13D/A- Amendment #6 – Former CEO Frank Reynolds now owns 4,913,260 (4.8%). This should be his last SC 13D/A filing since he now owns less then 5% of the shares outstanding.
Feb 5 - InVivo announces the appointment of Mark D. Perrin as Chairman of InVivo’s Board of Directors, effective immediately.
Feb 9 - InVivo today announced the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (CMO), effective March 2, 2015. Prior to joining the InVivo team, Dr. Masuoka served as Senior VP and CMO at Cubist Pharmaceuticals from July 2013 until Jan 2015. FactMan: Merck acquired Cubist in January for $102 a share ($9.5 billion buyout). Interesting that she chose InVivo because with her credentials I am sure she could have picked a much larger company as her next place of employment. Clearly, a very strong hire.
Feb 23 - Froedtert & the Medical College of Wisconsin (MCW) Froedtert Hospital in Milwaukee, WI has been added as the 7th clinical site in the company’s acute SCI pilot study.
Feb 24 - Investor Presentation updated
Mar 2 - Our new CMO Lorianne Masuoka starts and receives 500,000 options to purchase InVivo shares at a price of $3.02. FactMan: She now has a big incentive to see the PPS rise well above $3.02 or $12.08 post reverse split.
Mar 3 – Video of Jesi transferring into a car posted on the “Jesi's Medical Expenses gofundme” website.
Mar 11 - InVivo reports 2014 Year End Financial Results and Business update:
-In the months that followed, an appreciable improvement in the first subject’s motor and sensory function was reported (improved from AIS A to C) as well as complete recovery of bowel function and improvement in bladder function. FactMan: fantastic news for InVivo, their shareholders and especially Jordan.
-In the future, we may attempt to further enhance the performance of our Neuro-Spinal Scaffold by multiple combination strategies involving electrostimulation devices, additional biomaterials, drugs approved by the FDA or growth factors.
-We are also evaluating a family of resorbable hydrogels for localized cell therapies for spinal cord injury. FactMan: looks like hydrogels may be back on the table soon.
Mar 23 - Video of Jesi moving her leg posted on the “Jesi S - NVIV Investor's Give gofundme” website. Zack’s¬ analyst Jason Napodano states: “That little move right there moves her from AIS-A to AIS-B or AIS-C at ~55 day.” FactMan: fantastic news for InVivo, their shareholders and especially Jesi.
Mar 24 - InVivo announces 1-for-4 reverse stock split in preparation for planned uplisting to NASDAQ. FactMan: In addition to improving the visibility of InVivo shares to investors, enhancing trading liquidity and broadening the potential institutional shareholder base, InVivo gets the opportunity to be included in indexes such as the NASDAQ as well as the Russell 2000 & 3000. InVivo will also have a greater chance to receive analyst coverage.
Mar 25 - the Keck Hospital of University of Southern California (USC) in Los Angeles, CA has been added as the 8th clinical site in the company’s acute SCI pilot study. Patrick Hsieh, MD, Director of Neurosurgery Spine Program stated “We look forward to contributing our years of expertise in spinal cord injury research, which includes using stem cells for spinal cord injury.”
Mar 26 - InVivo announces the reopening of concurrent enrollment of subjects 3, 4 and 5 in the company’s acute SCI pilot study. To date, there have been no reported serious safety events related to the Neuro-Spinal Scaffold or the procedure to implant the Neuro-Spinal Scaffold with the study’s first and second subjects.
Mar 27 - at the 66th Southern Neurosurgical Society Annual Meeting on March 25-28, 2015. CMO Lorianne Masuoka said: “It was gratifying to see a large neurosurgical audience exposed to our investigational product and implantation procedure.”
Mar 30 - InVivo announces that the University of Kansas Medical Center in Kansas City, KS has been added as the 9th clinical site in the company’s acute SCI pilot study.
Just the facts,
-FactMan777
